Related Experiment Videos
Antihypertensive agents, serum lipoproteins and glucose metabolism
P Ferrari1, J Rosman, P Weidmann
1Medizinische Poliklinik, University of Berne, Switzerland.
Insights
Traditional blood pressure medications like diuretics and beta blockers effectively reduce stroke but not heart issues. Some increase risks like high LDL cholesterol and poor glucose control, while others are metabolically neutral or beneficial.
Area of Science:
- Cardiovascular Pharmacology
- Metabolic Effects of Antihypertensives
Background:
- Traditional antihypertensive therapies, including diuretics and beta blockers, reduce cerebrovascular events but inadequately address coronary complications.
- Concerns exist regarding the unfavorable impact of conventional treatments on coronary risk factors beyond hypertension.
Purpose of the Study:
- To evaluate the metabolic effects of various antihypertensive drug classes on lipoprotein and carbohydrate profiles.
- To identify antihypertensive agents with neutral or potentially beneficial metabolic profiles.
Main Methods:
- Comparative analysis of metabolic effects (lipoprotein and glucose metabolism) of different antihypertensive drug classes.
- Review of existing literature on thiazide diuretics, beta blockers, calcium channel blockers, angiotensin converting-enzyme inhibitors, and alpha 1-receptor blockers.
Main Results:
- Thiazide diuretics can worsen glucose tolerance and increase atherogenic LDL cholesterol and triglycerides.
- Beta blockers (without intrinsic sympathomimetic activity) raise triglycerides and lower HDL cholesterol; some impair glucose tolerance, especially with diuretics.
- Calcium channel blockers, ACE inhibitors, and alpha 1 blockers show neutral or beneficial effects on lipid and carbohydrate profiles, with ACE inhibitors and alpha 1 blockers potentially improving insulin sensitivity and lipid metabolism, respectively.
Conclusions:
- Certain conventional antihypertensive drugs may adversely affect metabolic risk factors, including dyslipidemia and glucose intolerance.
- Angiotensin converting-enzyme inhibitors and alpha 1-receptor blockers appear metabolically neutral or beneficial, offering potential advantages in managing cardiovascular risk.
- Further research is needed to clarify the prognostic significance of drug-induced metabolic changes.
Abstract:
Effective blood pressure control with traditional high-dose diuretic therapy has led to a distinct decrease in cerebrovascular morbidity and mortality, but failed to achieve a satisfactory reduction of coronary complications and sudden death. The same applies also for beta blockers, although they have been shown to be effective in secondary prevention of myocardial infarction. It is suspected that conventional antihypertensive treatment has an unfavorable effect on coronary risk factors other than hypertension. For instance, thiazide-type diuretics can impair glucose tolerance and increase the potentially atherogenic serum low-density lipoprotein (LDL) cholesterol fraction and triglycerides. Beta blockers without partial intrinsic sympathomimetic activity increase serum triglycerides and tend to lower the potentially antiatherogenic high-density lipoprotein (HDL) cholesterol. Certain beta blockers may also impair glucose tolerance, particularly when they are combined with diuretics. Calcium channel blockers, angiotensin converting-enzyme inhibitors and alpha 1-receptor blockers do not adversely affect lipoprotein or carbohydrate profiles. The latter two drug classes may even increase insulin sensitivity, and alpha 1 blockers may also slightly improve lipid metabolism. The prognostic relevance of drug-induced dyslipidemia and/or glucose intolerance awaits further clarification. In the meantime, it is of clinical interest that several of the generally available antihypertensive drugs seem to be metabolically neutral or sometimes perhaps even potentially beneficial with regard to the lipoprotein and carbohydrate metabolism.